ArticleBlood2012
miR-155 regulates HGAL expression and increases lymphoma cell motility.
Article in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 72 citations in OpenAlex.
- The Role of microRNAs as Potential Biomarkers in Diffuse Large B-Cell Lymphoma.Non-coding RNA · 2026Review
- The Role of microRNA-155 as a Biomarker in Diffuse Large B-Cell Lymphoma.Biomedicines · 2024Review
- Regulation of BCR-dependent germinal center B-cell formation by HGAL and insight into its emerging myeloid ortholog, C1ORF150.Frontiers in immunology · 2024Review
- Lymphoma in Border Collies: Genome-Wide Association and Pedigree Analysis.Veterinary sciences · 2023Article
- LncRNA CASC2 Regulate Cell Proliferation and Invasion by Targeting miR-155/SOCS1 Axis in Hepatocellular Carcinoma.Journal of oncology · 2023Article
- MicroRNA-regulated B cells in obesity.Immunometabolism (Cobham, Surrey) · 2022Review
- Hierarchical graph attention network for miRNA-disease association prediction.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- MicroRNA signature in classical Hodgkin lymphoma.Journal of applied genetics · 2021Review
- Conditional expression of HGAL leads to the development of diffuse large B-cell lymphoma in mice.Blood · 2021Article
- MiR-31 promotes Th22 differentiation through targeting Bach2 in coronary heart disease.Bioscience reports · 2019Article
- Selective Histone Deacetylase 6 Inhibition Normalizes B Cell Activation and Germinal Center Formation in a Model of Systemic Lupus Erythematosus.Frontiers in immunology · 2019Article
- Melatonin Inhibits the Progression of Hepatocellular Carcinoma through MicroRNA Let7i-3p Mediated RAF1 Reduction.International journal of molecular sciences · 2018Article
- MicroRNA-31 Reduces the Motility of Proinflammatory T Helper 1 Lymphocytes.Frontiers in immunology · 2018Article
- MicroRNAs as Biomarkers of B-cell Lymphoma.Biomarker insights · 2018Review
- miRNAs in Normal and Malignant Hematopoiesis.International journal of molecular sciences · 2017Review
- Induction of miR-155 after Brain Injury Promotes Type 1 Interferon and has a Neuroprotective Effect.Frontiers in molecular neuroscience · 2017Article
- Article
- Article
- miR-155 as a Biomarker in B-Cell Malignancies.BioMed research international · 2016Review
- MicroRNAs in Lymphoma: Regulatory Role and Biomarker Potential.Current genomics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
HGAL, a prognostic biomarker in patients with diffuse large B-cell lymphoma and classic Hodgkin lymphoma, inhibits lymphocyte and lymphoma cell motility by activating the RhoA signaling cascade and interacting with actin and myosin proteins. Although HGAL expression is limited to germinal center (GC) lymphocytes and GC-derived lymphomas, little is known about its regulation. miR-155 is implicated in control of GC reaction and lymphomagenesis. We demonstrate that miR-155 directly down-regulates HGAL expression by binding to its 3'-untranslated region, leading to decreased RhoA activation and increased spontaneous and chemoattractant-induced lymphoma cell motility. The effects of miR-155 on RhoA activation and cell motility can be rescued by transfection of HGAL lacking the miR-155 binding site. This inhibitory effect of miR-155 suggests that it may have a key role in the loss of HGAL expression on differentiation of human GC B cells to plasma cell. Furthermore, this effect may contribute to lymphoma cell dissemination and aggressiveness, characteristic of activated B cell-like diffuse large B-cell lymphoma typically expressing high levels of miR-155 and lacking HGAL expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.